Building AI-ready Cultures in Life Sciences R&D
Life sciences are over‑funding AI and underneath‑funding the info maturity required to scale it. This imbalance is popping a possible R&D accelerant right into a excessive‑priced bottleneck that fails to ship compounding returns throughout the portfolio. These workflows depend on fragmented information sources spanning molecular databases, medical trial registries, inner protocols, and revealed literature. This…
